Polina Stepensky
Hadassah Medical Organization · Hadassah Hebrew University · Hadassah university hospital of Jerusalem
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Polina Stepensky as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:04 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07874334 · Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain AmyloidosisHadassah Medical Organization · not yet recruiting · Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis · principal investigator
- Ph2NCT04731298 · Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.Swedish Orphan Biovitrum · terminated · Graft Failure · principal investigator
- Ph1NCT04720313 · NXC-201 (Formerly HBI0101) Multiple MyelomaHadassah Medical Organization · active not recruiting · Dose Escalation and Safety · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:04 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- 289 citationsRCR 9.2
- 158 citationsRCR 4.9
- 52 citationsRCR 1.5
- Treatment of severe forms of LPS-responsive beige-like anchor protein deficiency with allogeneic hematopoietic stem cell transplantation.J Allergy Clin Immunol · 201847 citationsRCR 1.8
- Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.Lancet Haematol · 202340 citationsRCR 4.3
- Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis.Clin Cancer Res · 202233 citationsRCR 2.3
- Reticular dysgenesis: international survey on clinical presentation, transplantation, and outcome.Blood · 201732 citationsRCR 1.1
- Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.Haematologica · 202331 citationsRCR 2.1
- Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study.Transplant Cell Ther · 202230 citationsRCR 2.5
- Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis.J Clin Oncol · 202526 citationsRCR 7.2